WSJournal. Unmeltable, Uncrushable: The Holy Grail in

New Post Public Reply Private Reply Replies (0) Message Board
PoemStone

WSJournal. Unmeltable, Uncrushable: The Holy Grail in Painkillers.

The arms race to build a safer painkiller is under way.

In the wake of a key decision by the Food and Drug Administration, more than a dozen pharmaceutical companies—from startups to Pfizer Inc. PFE -0.83% —are vying to create painkilling drugs that are difficult to abuse.

The FDA moved last month to block the manufacture and sale of generic versions of the original OxyContin, which has gone off patent but which is easier to abuse than the current version. A newer version of OxyContin, introduced by its maker, Purdue Pharma LP, in 2010, contains an infusion of polymer that makes the pill difficult to crush, meaning addicts can't get all of the extended-release ingredients at once to get high.

This week, the FDA must consider the effectiveness of another safeguarded, brand-name painkiller, Endo Pharmaceuticals Inc.'s ENDP +0.90% Opana ER. If the FDA thinks Opana ER slows abuse, the agency can shield Endo from the competition—since the generics don't have any abuse-deterrents.

Such a decision would send a strong message to pharmaceutical makers that pain drugs with no safeguards are likely to be removed from the market—and that there are billions of dollars in potential revenue to be had from the sale of painkillers that are abuse proof.

The FDA moved last month to block the manufacture and sale of generic versions of the original OxyContin, which has gone off patent but which is easier to abuse than the current version. A newer version of OxyContin, introduced by its maker, Purdue Pharma LP, in 2010, contains an infusion of polymer that makes the pill difficult to crush, meaning addicts can't get all of the extended-release ingredients at once to get high.

image


As a result, companies such as Pfizer, Johnson & Johnson JNJ -1.25% and Endo are trying to crack that potentially lucrative market. Pfizer wants to introduce Remoxy, a direct OxyContin competitor with abuse deterrents, and a morphine drug called Embeda

Johnson & Johnson is conducting tests to demonstrate abuse-deterrent properties of its opioid for moderate to severe pain. Purdue Pharma wants to adapt its abuse-deterrent technology for a hydrocodone product—a class of drugs currently dominated by low-cost generics that don't have abuse-proof formulations.

"Over time, it should be a scientific race across the whole pharmaceutical industry to create a market where all opioids have abuse-deterrent properties," said Gary L. Stiles, senior vice president of research and development at the closely held Purdue Pharma.

The race could give a boost to an already lucrative market and raise the cost of pain treatment. A recent Cowen & Co. report predicts an increase in prescription pain drug sales of more than 15% by 2017, reaching $8.4 billion, thanks in part to the FDA ruling. It could also bring about a reshuffling of market share in the fast-growing $7.3 billion pain market, as companies such as Pfizer move with full force in the opioid painkiller market for the first time.

The FDA isn't directly requiring all painkillers to have safeguards. But should an effective abuse-deterrent drug be developed, the FDA said it has the power to remove on-the-market rival products which don't.

Drug companies are racing to conduct the studies and research required by the FDA to prove their drugs thwart abuse. Winning that distinction from the FDA, as Purdue Pharma has done for OxyContin, allows company sales representatives to tout those properties to doctors—forming a potential new marketing battleground for branded drugs. "That's how you're going to see the battle going forward," said Mike Royal, chief of clinical affairs at AcelRx Pharmaceuticals Inc., ACRX +3.97% which is developing treatments for acute pain.

Pfizer could grab more of the prescription painkiller market, based on its product pipeline and ability to successfully market new drugs, analysts said. Endo currently leads the pain management drugs market with a 30% share, followed by Purdue Pharma's 28% share, according to a recent Cowen & Co. report. Pfizer had just 5%, according to Cowen.

Pfizer has been lying in wait. The company's $3.6 billion acquisition of King Pharmaceuticals in 2011 took it into the opioid market. In addition to Remoxy and Embeda, Pfizer owns the rights to at least five other painkillers.

Remoxy is protected from abuse by a type of sugar sucrose that is used in orange soda or energy drinks. It prevents the medication from splitting apart or separating under the duress of heat or being mixed with alcohol, said James E. Brown, chief executive of Durect Corp., which developed Remoxy with Pain Therapeutics Inc. PTIE +3.77% before selling it to King.

The FDA rejected approval of Remoxy in 2011, but Pfizer met with the FDA in March and is discussing the "next steps" to address the issues raised, said John Young, Pfizer's president of primary-care business, on a Tuesday earnings call with analysts. "We believe we have a path forward," he said, adding Embeda could launch in the first half of 2014.

The FDA is expected to decide Friday whether Endo's Opana, which turns into a jellylike substance when abusers heat it up for injection, can be marketed to physicians as having abuse-deterrent features.

Johnson & Johnson is also conducting studies to show the abuse-deterrent properties of Nucynta ER and plans on meeting with the FDA later this year to review it, said Gary Vorsanger, senior director of clinical development at the company's Janssen Pharmaceuticals unit.

Purdue Pharma, for its part, says it is looking for ways to use the OxyContin technology on other drugs, like other formulations of oxycodone, morphine and hydrocodone.

Smaller biotech firms are crafting their own safeguards. Egalet Ltd., of Malvern, Pa., has turned to a plastic injection molding manufacturing technique used to make Legos or plastic bottle caps. The pills are so hard that when placed in a coffee grinder—a common way to break down pills by abusers—the blades get chipped. "It's a very physically imposing pill," said Bob Radie, Egalet's chief executive.

North Liberty, Iowa-based KemPharm Inc. is developing a hydrocodone product bonded with a common additive—benzoic acid—that's used to prevent growth of mold and other bacteria in foods like pickles, yogurt and beer. Addicts trying to inject or inhale the pills won't feel a thing, because the medication can only be broken down by powerful enzymes in the stomach or intestinal track.

"What you get, essentially, is nothing. It's no better than ordinary table salt or sugar," said KemPharm Chief Executive Travis Mickle.

The Wall Street Journal

Featured stocks: Coffee Shoppe
For conservative debate: "Keeping it Real"
Game Changing stock $SHMP

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AMD Faces Fresh Scrutiny Over China Supply Exposure

Updated Category News Views 72

One nasty report can turn a chip giant’s supply chain into a flashing red light, and that is precisely the mess confronting Advanced Micro Devices investors this week. Shares fell more than 7.7% on November 19 after Hunterbrook Media published allegations involving China-linked sales, firmware and manufacturing relationships. Then, on November 20, shareholder-rights...

Continue Reading
MTI Adds Aviation Veterans as Acorn Builds MRO Plan

Updated Category News Views 117

Two old hands entering a boardroom can matter more than another glossy growth slogan, especially in aircraft maintenance, where a delayed part can ground an airplane and turn a customer relationship sour in a hurry. MTI Aviation has added Tony DiSimone Sr. and Aviv Tzur to its board, a move announced November 20, 2026, after Acorn Capital Management took a majority...

Continue Reading
ECW Puts $52 Million Behind Learning Through Crisis

Updated Category News Views 66

A reserve fund for a classroom is not glamorous, but it may be the smartest detail in this whole $52 million commitment. Education Cannot Wait has announced support for more than 300,000 children in Lebanon, Myanmar and South Sudan, where war, flooding and displacement have ripped ordinary schooling apart. The money is meant to restore learning, provide catch-up classes...

Continue Reading
Northgate’s Stanton Opening Puts Community Work First

Updated Category News Views 86

A 55,721-square-foot grocery opening can look like ordinary retail churn until you notice where the money and attention are landing. Northgate González Market’s new Stanton location arrives ahead of Thanksgiving, yes, but the more telling detail is the company’s decision to pair a major store launch with 375 jobs and more than $30,000 directed toward families,...

Continue Reading
Travel Disruptions Reveal the Value of Human Support

Updated Category News Views 61

Air travel’s ugly little secret surfaced again during the recent ground stop: a reservation is easy, but rescuing a trip is labor-intensive, fast-moving work. Internova Travel Group says its people across Travel Leaders Network, Global Travel Collection and ALTOUR moved quickly as cancellations piled up and travelers were left staring at busted itineraries. That is not...

Continue Reading
Great Rail Journeys Bets Bigger on Luxury Rail in 2027

Updated Category News Views 99

A $19,995 vacation is not selling a seat on a train; it is selling relief from planning, crowds and compromise. Great Rail Journeys is leaning hard into that proposition for 2027 with two additions to its premium Landmark Collection: a Europe-heavy Orient Express and Rhône cruise pairing, plus a South Africa itinerary built around safari, Victoria Falls and rail-flavored...

Continue Reading
Sprocket’s GigaOm Leap Puts PTaaS Claims Under Scrutiny

Updated Category News Views 44

Security vendors love a shiny quadrant, but this one deserves more than the usual polite golf clap. Sprocket Security moved from Challenger and Outperformer in GigaOm’s 2025 Penetration Testing as a Service assessment to a Leader in the version 5 report released in 2026. That is a meaningful jump in a category where buyers are tired of annual testing reports that go...

Continue Reading
Fraud0-FouAnalytics Takes Aim at Legacy Ad Verification

Updated Category News Views 25

Digital ad measurement has spent years grading its own homework, and that little arrangement may finally be getting some daylight. fraud0 and FouAnalytics say their expanded partnership will give advertisers impression-level visibility into where ads actually rendered, whether apparent humans engaged with them, and where wasted Google Ads spend might be recoverable. The...

Continue Reading
Duetti, CesiumAstro, and a Busy NYSE Capital Morning

Updated Category News Views 78

Three very different piles of money are jamming up the November 20 NYSE slate, and that contrast is the whole point. Private music catalogs, space-and-defense communications, and a new stock-and-bond ETF do not belong in the same bucket. Yet all three are competing for investor attention before the opening bell, alongside Danaos Corporation's 20th listing anniversary....

Continue Reading
Why Insurance Must Change as Family Assets Keep Growing

Updated Category News Views 32

A policy bought in the starter-home years can turn stale quietly while everything around it gets bigger, pricier and more complicated. That is the uncomfortable little truth behind Daniel C. DiCocco's discussion in HelloNation: families often treat insurance as a box checked long ago, even as they add property, savings, debt, children and fresh responsibilities. Static...

Continue Reading

Top 5 Most Recently Viewed Articles

Anticipating Earnings: Barfresh Food Group's Upcoming Report

Updated Category News Views 61

Anticipating Earnings: Barfresh Food Group's Upcoming Report Barfresh Food Group (NASDAQ: BRFH) is on the brink of releasing its quarterly earnings. Investors are keenly awaiting the announcement, scheduled for Thursday. As the date approaches, it is crucial to analyze the expectations and historical performance of the company. The consensus among analysts is that...

Continue Reading
Meta's Smart Glasses: AI Performance Lags Behind ChatGPT's

Updated Category News Views 563

Meta's AI Tools Tested Against ChatGPT Recently, Gene Munster from Deepwater Asset Management conducted a head-to-head comparison of Meta Platforms Inc.'s AI capabilities on its smart glasses and the performance of OpenAI's ChatGPT. His findings highlighted significant gaps between the two AI systems. ChatGPT Outshines Meta AI in Tests During the evaluation, Munster...

Continue Reading
Tractor Supply Company Expands Offerings with Allivet Acquisition

Updated Category News Views 79

Tractor Supply Company to Acquire Allivet Tractor Supply Company (NASDAQ: TSCO), the top retailer for rural lifestyle in the U.S., has made an exciting announcement regarding its latest acquisition. The company has signed a definitive agreement to acquire Allivet, an esteemed private online pharmacy specializing in pet and animal health. This strategic move aims to...

Continue Reading
20+ Companies Break Ground in Urticaria Treatment Innovations

Updated Category News Views 236

Overview of Urticaria Treatment Innovations Urticaria, commonly known as hives, is a skin condition characterized by raised, itchy welts that can vary in size and location. The increasing prevalence of urticaria has spurred significant growth in treatment options, with various companies leading clinical trials dedicated to developing new therapies. Factors contributing to...

Continue Reading
Alphabet's Unique AI Strategy: A Competitive Edge Over Rivals

Updated Category News Views 241

Alphabet's AI Transformation and Competitive Advantage Alphabet Inc. (NASDAQ: GOOGL), a leader in technology innovation, is transforming its approach to artificial intelligence. The company, trading at $319.08 per share and boasting a market capitalization of $3.79 trillion, is narrowing the valuation gap with notable competitors. Its advancements in Tensor Processing...

Continue Reading